AzTrials
AzTrials

Coronary Artery Bypass Graft (CABG)PROTECT-CABGNCT07302659

Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG

A study testing Aortic no-touch coronary artery bypass grafting (RIMA-SVG) and Conventional off-pump CABG with partial clamping of the ascending aorta (Ao-SVG) in people with Coronary Artery Bypass Graft (CABG), run by China National Center for Cardiovascular Diseases at 4 sites in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

To explore surgical strategies that reduce perioperative neurologic complications in cardiovascular surgery, with the aim of improving perioperative outcomes and quality of life while reducing the socioeconomic burden. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Coronary Artery Bypass Graft (CABG)
What is being tested?
Aortic no-touch coronary artery bypass grafting (RIMA-SVG) and Conventional off-pump CABG with partial clamping of the ascending aorta (Ao-SVG)
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
380 participants
Where
4 sitesChina
Study dates
10 Mar 2026to 30 Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients (>18 years old) with multivessel coronary artery disease who are scheduled to undergo isolated off-pump coronary artery bypass grafting and who provide informed consent to participate in this study.

Who cannot join

  • Indications for cardiopulmonary bypass surgery (or no contraindications to on-pump surgery);
  • Great saphenous vein is unsuitable for use as a graft conduit;
  • Subclavian artery stenosis or occlusion, or any contraindication to the use of the internal mammary artery as a graft conduit;
  • History of previous cardiac surgery;
  • Emergency surgery;
  • Inability to apply an aortic clamp due to severe ascending aortic calcification;
  • Expected inability to tolerate MRI or contraindications to MRI (e.g., known intolerance to MRI, an implanted permanent pacemaker, or an anticipated need for permanent pacemaker implantation);
  • Inability to complete neurocognitive assessment due to language barriers or visual/hearing impairment.

Trial locations and contacts

4 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Lianxin Chen contact

01088322265

chenlianx1@163.com

China4 sites, 4 recruiting
  • Fuwai Hospital Chinese Academy of Medical Sciences

    Beijing

    Chen, 01088322265, chenlianx1@163.com

    Recruiting
  • Peking University First Hospita

    Beijing

    Wang, +86 13522784537, wj0463@sina.cn

    Not yet recruiting
  • Qingdao Cardiovascular Hospital

    Qingdao

    Feng, +86 13964265680, fengzunyi@163.com

    Not yet recruiting
  • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen

    Shenzhen

    Nie, +86 13701176101, wangsymd@126.com

    Not yet recruiting

Other trials in China

About this study

Official title: Surgical Techniques to Prevent Perioperative Neurologic Complications in Patients Undergoing Coronary Artery Bypass Grafting

To explore surgical strategies that reduce perioperative neurologic complications in cardiovascular surgery, with the aim of improving perioperative outcomes and quality of life while reducing the socioeconomic burden. Specifically:

This multicenter, randomized controlled clinical trial will evaluate the benefits of a novel aortic no-touch technique in reducing perioperative silent brain infarction(SBI) among patients undergoing surgical treatment for coronary artery disease. The findings are expected to provide a safe and effective myocardial revascularization strategy for individuals at high risk of cerebral ischemia.

Being tested
Aortic no-touch coronary artery bypass grafting (RIMA-SVG), Conventional off-pump CABG with partial clamping of the ascending aorta (Ao-SVG)
Keywords
coronary artery bypass graft, Silent Brain Infarction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Aortic no-touch coronary artery bypass grafting (RIMA-SVG)Procedure or surgery

    Ascending aortic no-touch CABG with saphenous vein graft (SVG) anastomosed to the right internal mammary artery (RIMA)

  • Conventional off-pump CABG with partial clamping of the ascending aorta (Ao-SVG)Procedure or surgery

    Off-pump CABG with proximal saphenous vein graft (SVG) anastomoses constructed on the ascending aorta using a partial-occlusion (side-biting) clamp.

Study groups in NCT07302659
Study groupRoleWhat they receive
Traditional off-pump coronary artery bypass grafting (Ao-SVG)Active comparatorOff-pump CABG with proximal saphenous vein graft (SVG) anastomoses constructed on the ascending aorta using a partial-occlusion (side-biting) clamp.
Receives: Procedure: Conventional off-pump CABG with partial clamping of the ascending aorta (Ao-SVG)
Aortic no-touch coronary artery bypass grafting (RIMA-SVG)ExperimentalAortic no-touch off-pump CABG in which the saphenous vein graft (SVG) is anastomosed to the right internal mammary artery (RIMA) as a composite graft, avoiding any clamping or manipulation of the ascending aorta.
Receives: Procedure: Aortic no-touch coronary artery bypass grafting (RIMA-SVG)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Saphenous vein graft (SVG) occlusion rate

    Assessed by coronary computed tomography angiography (CCTA)

    Measured: 1 year after surgery

  2. New-onset clinical stroke and silent brain infarction (SBI)

    Clinical stroke and SBI assessed at 7 ± 3 days postoperatively; SBI assessed by brain magnetic resonance imaging (MRI).

    Measured: 7 ± 3 days after surgery

Secondary outcomes (12)
  1. Incidence of postoperative delirium

    The incidence of delirium evaluated by CAM/CAM-ICU

    Measured: within 5 postoperative days

  2. Incidence of perioperative neurocognitive disorder (PND)

    Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA).

    Montreal Cognitive Assessment (MoCA; range 0-30 points, higher scores indicate better cognitive function).

    Measured: within 7 days after surgery

  3. Perioperative major adverse cardiovascular and cerebrovascular events (MACCE)

    Major adverse cardiovascular and cerebrovascular events are defined as the composite of all-cause death, myocardial infarction, stroke and repeat revascularization.

    Measured: within 30 postoperative days

  4. MACCE within 3 months after surgery

    Major adverse cardiovascular and cerebrovascular events are defined as the composite of all-cause death, myocardial infarction, stroke and repeat revascularization.

    Measured: Up to 3 months after surgery (3-month follow-up)

  5. Clinical stroke within 3 months after surgery

    Measured: Up to 3 months after surgery (3-month follow-up)

  6. Sternal complications within 3 months after surgery

    Measured: Up to 3 months after surgery (3-month follow-up)

  7. Cognitive dysfunction at 3 months after surgery

    Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA).

    Montreal Cognitive Assessment (MoCA; range 0-30 points, higher scores indicate better cognitive function).

    Measured: 3 months after surgery

  8. Angina within 12 months after surgery

    Patients will complete the Seattle Angina Questionnaire (SAQ) at baseline pre-procedure and again at 12 months post CABG

    Measured: 12 months after surgery

  9. Cognitive dysfunction at 12 months after surgery

    Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA).

    Montreal Cognitive Assessment (MoCA; range 0-30 points, higher scores indicate better cognitive function).

    Measured: 12 months after surgery

  10. Sternal complications within 12 months after surgery

    Measured: Up to 12 months after surgery (12-month follow-up)

  11. Clinical stroke within 12 months after surgery

    Measured: Up to 12 months after surgery (12-month follow-up)

  12. MACCE within 12 months after surgery

    Major adverse cardiovascular and cerebrovascular events are defined as the composite of all-cause death, myocardial infarction, stroke and repeat revascularization.

    Measured: Up to 12 months after surgery (12-month follow-up)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2025
  2. Study start10 Mar 2026
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion30 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
380 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07302659
Sponsor's protocol ID
2023ZD0504701
Acronym
PROTECT-CABG
Status last verified
Apr 2026
First submitted
19 Nov 2025
Last updated
14 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Zhao DF, Edelman JJ, Seco M, Bannon PG, Wilson MK, Byrom MJ, Thourani V, Lamy A, Taggart DP, Puskas JD, Vallely MP. Coronary Artery Bypass Grafting With and Without Manipulation of the Ascending Aorta: A Network Meta-Analysis. J Am Coll Cardiol. 2017 Feb 28;69(8):924-936. doi: 10.1016/j.jacc.2016.11.071.

    PubMed 28231944
  • Tachibana H, Hiraoka A, Saito K, Naito Y, Chikazawa G, Tamura K, Totsugawa T, Yoshitaka H, Sakaguchi T. Incidence and impact of silent brain lesions after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2021 Feb;161(2):636-644. doi: 10.1016/j.jtcvs.2019.09.162. Epub 2019 Oct 16.

    PubMed 31735394

Questions about this trial

What is this clinical trial studying?

A study testing Aortic no-touch coronary artery bypass grafting (RIMA-SVG) and Conventional off-pump CABG with partial clamping of the ascending aorta (Ao-SVG) in people with Coronary Artery Bypass Graft (CABG), run by China National Center for Cardiovascular Diseases at 4 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Lianxin Chen (01088322265, chenlianx1@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Saphenous vein graft (SVG) occlusion rate (time frame: 1 year after surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07302659, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in